Jing Wang

pfizer china

H指数:21

被引数:2,539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vitamin E and related tocols in Cancer: Unraveling the Paradox of Antioxidant and Pro-Oxidant Roles

维生素E及相关类维生素在癌症中的作用：阐明抗氧化与促氧化作用的矛盾

The Journal of Nutritional Biochemistry

IF0

2026-01-120

PRE

Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer

广泛期小细胞肺癌免疫化疗的昼夜时间对总生存期的影响

CANCER

IF5.1

2025-12-150

PRE

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults

Clinical Pharmacology in Drug Development

IF1.8

2025-10-010

OAAI

Machine learning predicts severe adverse events and salvage success of CT-guided lung biopsy after nondiagnostic transbronchial lung biopsy

机器学习预测经皮肺活检在经支气管肺活检诊断不明后的严重不良事件和挽救成功率

European Radiology

IF4.7

2025-09-220

PRE

Phyllodes Tumor of The Breast in Hispanic Population: A Clinicopathological Study of 226 Cases

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

Echinacoside inhibits tumor immune evasion by downregulating inducible PD-L1 and reshaping tumor immune landscape in breast and colorectal cancer

松果菊苷通过下调诱导PD-L1和重塑乳腺癌和结直肠癌的肿瘤免疫景观来抑制肿瘤免疫逃避

PHYTOMEDICINE

IF8.3

2024-12-010

PRE

Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer

PARP抑制剂联合免疫检查点抑制剂在卵巢癌中的应用

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2024-08-212

OAAI

Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis

RESEARCH

IF10.7

2024-05-241

OAAI

Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Roles of TRPM7 in ovarian cancer

BIOCHEMICAL PHARMACOLOGY

IF5.6

2023-11-012

OAAI

Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

PRE

SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

晚期上皮性卵巢癌新辅助化疗后间隔切除手术和术后化疗的时机: 一项多中心的真实世界研究

JOURNAL OF OVARIAN RESEARCH

IF4.2

2023-06-273

OAAI

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes

ONCOGENE

IF7.3

2022-04-2510

PRE

Computational methods, databases and tools for synthetic lethality prediction

BRIEFINGS IN BIOINFORMATICS

IF7.7

2022-03-2920

OAAI

Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

SCIENTIFIC REPORTS

IF3.9

2021-03-3013

OAAI

PARP inhibitor resistance: the underlying mechanisms and clinical implications

MOLECULAR CANCER

IF33.9

2020-06-20317

OAAI

Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions

MODERN PATHOLOGY

IF5.5

2020-01-0135

OAAI

LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-010

PRE

Efficacy and pharmacokinetics of niraparib in BRCA-mutant and wild-type intracranial triple negative breast cancer murine models

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Jing Wang

个人简介

教育背景

工作经历

荣誉奖项

研究方向